NCT00705588

Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Rabin Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pulmonary arterial hypertension is a chronic disease of the lung blood vessels resulting in constriction and high pressures. Treatment is given with a variety of drugs including the prostanoid class (e.g. epoprostenol, iloprost and the phosphodiesterase 5 (PDE-5) inhibitors (e.g. sildenafil). Although these drugs are known to be effective alone, little is known about combining them together in various combinations. In this trial we will add a long-acting PDE-5 inhibitor to the treatment of patients with pulmonary arterial hypertension who currently are receiving only a prostanoid drug.

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	Tadalafil	Orally, titrated to maximum 20mg od
DRUG	Vardenafil	Orally, titrated to 10 mg bid

Timeline

• Start date: 2008-08-01
• Primary completion: 2010-01-01
• First posted: 2008-06-26
• Last updated: 2008-06-26

Locations

1 site across 1 country: Israel